PD-1 inhibitors, nivolumab and pembrolizumab, were approved in 2014, and PD-L1 inhibitors, such as atezolizumab, avelumab, and durvalumab, were also approved in 2016 and 2017 for various cancers [4,5,6,7]. This evidence concerns the gene CD274 and cancer.